Integrative treatment possibilities of the inoperable pancreatic carcinoma - A review;Integrative therapiemöglichkeiten des inoperablen pankreaskarzioms - Eine übersicht

Deutsche Zeitschrift fur Onkologie

Volumn 40, Issue 3, 2008, Pages 106-110

  Matthes, Harald ^a   Buchwald, Dirk ^a   Kröz, Matthias ^a   Schad, Friedemann ^a  

^a Gemeinschaftskrankenhaus Havelhöhe ^*

Author keywords

Autovaccination; CAM; Integrative medicine; Intratumoral therapy; Mistletoe; Pancreatic carcinoma; Quality of life

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; CISPLATIN; GEMCITABINE; GLUTATHIONE; HELIXOR M; SELENIUM; TAMOXIFEN; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HOSPITALIZATION; HUMAN; IMMUNOTHERAPY; MONOTHERAPY; PANCREAS CARCINOMA; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; VISCUM ALBUM;

EID: 54349083569     PISSN: 16175891     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1082599     Document Type: Review

References (45)

1. Erlotinib: new indication. Metastatic cancer of the pancreas: palliative care is still the best option. Prescrire Int. 2008; 17: 6.
2. Adler G, Seufferlein T, Bischoff SC, et al: S3-Guidelines "Exocrine pancreatic cancer" 2007. Z Gastroenterol. 2007; 45: 487-523.
3. Argyriou AA, Chroni E, Koutras A, et al: A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer. 2006; 14: 1134-1140.
4. Argyriou AA, Polychronopoulos P, Iconomou G, et al: Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol. 2007; 46: 1131-1137.
5. Bokemeyer C, Lipp HP, Schmoll HJ: Akute und chronische Toxizität sowie Spättoxiität antineoplastischer Substanzen. In: Schmoll HJ, Höffken K, Possinger K (eds): Kompendium Internistischer Onkologie. Heidelberg: Springer; 2006: pp 1872-2010.
6. Braun C: Lebensqualität beim Pankreaskarziom. Saarbrücken: Dr. Müller Verlag AG; 2008.
7. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1976; 73: 3685-3689.
8. Cascinu S, Scartozzi M, Labianca R, et al: High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer. 2004; 90: 1521-1525.
9. Chang KJ, Lee JG, Holcombe RF, et al: Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol. 2008; 5: 107-111.
10. Chang KJ, Nguyen PT, Thompson JA, et al: Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound-guided fine-needle injection in patients with advanced pancreatic carcinoma. Cancer. 2000; 88: 1325-1335.
11. Colombo N, Bini S, Miceli D, et al: Weekly cisplatin +/- glutathione in relapsed ovarian carcinoma. Int J Gynecol Cancer. 1995; 5: 81-86.
12. Duffy A, Kortmansky J, Schwartz GK, et al: A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol. 2008; 19: 86-91.
13. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007; 18: 581-592
14. Hecht JR, Bedford R, Abbruzzese JL, et al: A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer. 2003; Res 9: 555-561.
15. Heinemann V, Quietzsch D, Gieseler F, et alR: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24: 3946-3952.
16. Hotz HG, Hines OJ, Masood R, et al: VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery. 2005; 137: 192-199.
17. House MG, Gonen M, Jarnagin WR, et al: Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg. 2007; 11: 1549-1555.
18. Kienle GS, Kiene H: Die Mistel in der Onkologie. Stuttgart: Schattauer Verlag; 2003.
19. Linghu E, Matthes K, Mino-Kenudson M, Brugge WR: Feasibility of endoscopic ultrasound-guided OncoGel (ReGel/paclitaxel) injection into the pancreas in pigs. Endoscopy 2007; 37: 1140-1142.
20. Matthes H: Intraläsionale Mistelinjektionen in Lebermetastasen bei kolorektalem Karzinom und in das primäre Hepatozelluläre Karzinom (HCC). Der Merkurstab. 1997; 50: 41.
21. Matthes H, Buchwald D, Schad F, Jeschke E: Intratumorale Applikation von Viscum album L (Mistelgesamtextrakt; Helixor M®) in der Therapie des inoperablen Pankreaskarziom. Z Gastroenterologie. 2007; 45:DOI: 10.1055/s-2007-988162.
22. Matthes H, Friedel E, Bock P: Supportive care in pancreatic carcinoma patients with the fermented mistletoe (Viscum album L.) extract Iscador treatment. FACT. 2007; 12: 35.
23. Matthes H, Friedel WE, Bock PR: Supportive care in pancreatic carcinoma patients of the fermented mistletoe (Viscum album L.) extract treatment. Annals of Oncology. 2007; 18:doi:10.1093/annonc/mdm1333|ix1199.
24. Matthes H, Friedel WE, Bock PR, Zänker KS (Publikation eingereicht) Improved supportive therapy of pancreatic carcinoma by mistletoe extract treatment within chemoand/or radiotherapy protocols vs. best supporive care: a multicenter, controlled, observational cohort study.
25. Matthes H, Friedel WE, Hanisch J, Karasmannc M, Bock PR: Improvement of the palliative supportive care in pancreatic carcinoma patients with a fermented mistletoe (Viscum album L.) extract treatment. Phytomedicine. 2007; 14: 54.
26. Matthes H, Schad F, Buchwald D, Schenk G: Endoscopic Ultrasound-Guided Fine-Needle Injection of Viscum Album L. (mistletoe; Helixor M) in the Therapy of Primary Inoperable Pancreas Cancer: a Pilot Study. Gastoenterology. 2005; 128: 433, T 988.
27. Matthes K, Mino-Kenudson M, Sahani DV, Holalkere N, Brugge WR: Concentration-dependent ablation of pancreatic tissue by EUS-guided ethanol injection. Gastrointest Endosc. 2007; 65: 272-277.
28. Matthes K, Mino-Kenudson M, Sahani D, et al: EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in the porcine pancreas (with video). Gastrointest Endosc. 2007; 65: 448-453.
29. Matthes K, Yusuf TE, Willingham FF, Mino-Kenudson M, Rattner DW, Brugge WR: Feasibility of endoscopic transgastric distal pancreatectomy in a porcine animal model. Gastrointest Endosc. 2007; 66: 762-766.
30. Müller-Oerlinghausen B, Klasek R, Düppenbecker H, Munter KH: Handbuch der unerwünschten Arzneimittelwirkungen. Jena: Urban & Fischer; 1999.
31. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. The New England journal of medicine. 2005; 350: 1200-1210.
32. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297: 267-277.
33. Pace A, Savarese A, Picardo M, et al: Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003; 21: 927-931.
34. Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer research. 2004; 24: 303-309.
35. Riess H: Antiangiogenic strategies in pancreatic cancer. Recent Results Cancer Res 2008; 177: 123-129.
36. Robert Koch-Institut: Krebs in Deutschland 2003-2004. Robert Koch-Institut; 2008.
37. Rostock M: Misteltherapie: Ihr aktueller Stellenwert bei der Behandlung von Tumorerkrankungen. Darmstadt: Steinkopff Verlag; 2000.
38. Saif MW: Anti-angiogenesis therapy in pancreatic carcinoma. JOP. 2006; 7: 163-173.
39. Saif MW: Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP. 2007; 8: 545-552.
40. Saif MW: Is there a standard of care for the management of advanced pancreatic cancer? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008. JOP. 2008; 9: 91-98.
41. Schad F, Teodoridis C, Albrecht U, et al: Das Netzwerk Onkologie: Aufbau und Etablierung eines Forschungsverbunds in der anthroposophisch orientierten onkologischen Medizin. Merkurstab. 2007; 3: 234-237.
42. Slidell MB, Chang DC, Cameron JL, et al: Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008; 15: 165-174.
43. Strumberg D, Oettle H, Heinemann V, Wilkowski R, Klempnauer J, Arnold D: Pankreaskarzinom. In: Schmoll HJ, Höffken K, Possinger K (eds): Kompendium Internistischer Onkologie. Heidelberg: Springer; 2006: pp 3969-3998.
44. Yamamoto S, Miyake I, Takatori K, Ohmoto K, Mitsui Y, Shimabara M: [Percutaneous ethanol injection for unresectable pancreatic cancer-report of two cases]. Gan To Kagaku Ryoho. 1998; 25: 1969-1971.
45. Yusuf TE, Matthes K, Brugge WR: EUS-guided photodynamic therapy with verteporfin for ablation of normal pancreatic tissue: a pilot study in a porcine model (with video). Gastrointest Endosc. 2008; 67: 957-961.